HRP20140262T1 - Biomarker za praä†enje pacijenata - Google Patents

Biomarker za praä†enje pacijenata Download PDF

Info

Publication number
HRP20140262T1
HRP20140262T1 HRP20140262AT HRP20140262T HRP20140262T1 HR P20140262 T1 HRP20140262 T1 HR P20140262T1 HR P20140262A T HRP20140262A T HR P20140262AT HR P20140262 T HRP20140262 T HR P20140262T HR P20140262 T1 HRP20140262 T1 HR P20140262T1
Authority
HR
Croatia
Prior art keywords
patient
specified
activated
levels
treatment
Prior art date
Application number
HRP20140262AT
Other languages
English (en)
Croatian (hr)
Inventor
Bruce Acres
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of HRP20140262T1 publication Critical patent/HRP20140262T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HRP20140262AT 2009-04-17 2010-04-12 Biomarker za praä†enje pacijenata HRP20140262T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09305328 2009-04-17
PCT/EP2010/054743 WO2010119003A1 (en) 2009-04-17 2010-04-12 Biomarker for monitoring patients

Publications (1)

Publication Number Publication Date
HRP20140262T1 true HRP20140262T1 (hr) 2014-04-25

Family

ID=42270292

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140262AT HRP20140262T1 (hr) 2009-04-17 2010-04-12 Biomarker za praä†enje pacijenata

Country Status (26)

Country Link
US (2) US20120058493A1 (enExample)
EP (1) EP2419728B1 (enExample)
JP (1) JP5661738B2 (enExample)
KR (1) KR20120027146A (enExample)
CN (1) CN102395883B (enExample)
AU (1) AU2010237215B2 (enExample)
BR (1) BRPI1010512A2 (enExample)
CA (1) CA2759050A1 (enExample)
CO (1) CO6440591A2 (enExample)
CR (1) CR20110513A (enExample)
CY (1) CY1114910T1 (enExample)
DK (1) DK2419728T3 (enExample)
ES (1) ES2445146T3 (enExample)
HR (1) HRP20140262T1 (enExample)
IL (1) IL214917A (enExample)
MX (1) MX2011010920A (enExample)
NZ (1) NZ594896A (enExample)
PL (1) PL2419728T3 (enExample)
PT (1) PT2419728E (enExample)
RU (1) RU2555340C2 (enExample)
SG (1) SG175060A1 (enExample)
SI (1) SI2419728T1 (enExample)
SM (1) SMT201400046B (enExample)
TW (1) TWI426270B (enExample)
WO (1) WO2010119003A1 (enExample)
ZA (1) ZA201107545B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6375947B2 (ja) * 2012-05-11 2018-08-22 味の素株式会社 取得方法、評価装置、評価方法、評価プログラム、評価システムおよび端末装置
US20140244556A1 (en) * 2013-02-27 2014-08-28 Abdul Saleh Methods for and apparatus generating automated pharmaco genetics correlation
US20200353107A1 (en) * 2017-12-08 2020-11-12 Stc.Unm In vivo imaging of tumor infiltration leukocytes
CN114859057A (zh) * 2022-04-13 2022-08-05 江苏省中医院 人结直肠癌或人结直肠癌转移的预测性生物标志物及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
AU672359B2 (en) 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
DE19520606B4 (de) 1995-06-06 2004-04-08 Roche Diagnostics Gmbh Vorrichtung zur optischen Untersuchung von Oberflächen
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1998004727A1 (en) 1996-07-25 1998-02-05 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
FR2751879B1 (fr) 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AU727308B2 (en) 1997-02-24 2000-12-07 Dana-Farber Cancer Institute Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2773885B1 (fr) 1998-01-16 2000-03-03 Elf Antar France Methode de caracterisation de la capacite de neutralisation d'un lubrifiant et dispositif pour la mise en oeuvre de cette methode
JP3119228B2 (ja) 1998-01-20 2000-12-18 日本電気株式会社 液晶表示パネル及びその製造方法
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
ES2220448T3 (es) 1999-02-04 2004-12-16 Geron Corporation Secuencias reguladoras de la transcripcion de la telomerasa transcriptasa inversa.
ATE332364T1 (de) 1999-02-22 2006-07-15 Transgene Sa Verfahren zur gewinnung von purifizierter virenzuammensetzung
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7001596B1 (en) 1999-11-15 2006-02-21 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
AUPQ520800A0 (en) 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
DE20122302U1 (de) 2000-11-23 2005-02-24 Bavarian Nordic A/S Variante des Modifizierten Vaccinia-Ankara-Virus
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
US20040133243A1 (en) 2002-07-26 2004-07-08 Santamore William P. Cardiac rhythm management system with intramural myocardial pacing leads and electrodes
MXPA05004588A (es) 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
FR2862648B1 (fr) 2003-11-21 2006-02-03 Biomerieux Sa Nouveau peptide immunogene et nouveaux epitopes et utilisations notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l 'hepatite c
ES2526344T3 (es) * 2005-06-28 2015-01-09 Oncothyreon Inc. Método para el tratamiento de pacientes con una vacuna de glicoproteína mucinosa (MUC-1)
CN101541342A (zh) * 2006-12-05 2009-09-23 特朗斯吉有限公司 产生提高的免疫应答的手段和方法
BRPI0913108A2 (pt) * 2008-05-29 2017-06-20 Trangene S A método ex-vivo para testar se um paciente responderá terapeuticamente a um método de tratamento, uso de níveis de células exterminadores naturais ativadas como um biomarcador, e, kit

Also Published As

Publication number Publication date
WO2010119003A1 (en) 2010-10-21
BRPI1010512A2 (pt) 2016-03-15
HK1163246A1 (en) 2012-09-07
EP2419728B1 (en) 2014-01-08
SMT201400046B (it) 2014-05-07
ZA201107545B (en) 2012-07-25
ES2445146T3 (es) 2014-02-28
CN102395883A (zh) 2012-03-28
US20140141039A1 (en) 2014-05-22
NZ594896A (en) 2013-07-26
CY1114910T1 (el) 2016-12-14
SI2419728T1 (sl) 2014-03-31
EP2419728A1 (en) 2012-02-22
CO6440591A2 (es) 2012-05-15
SG175060A1 (en) 2011-11-28
TWI426270B (zh) 2014-02-11
PL2419728T3 (pl) 2014-05-30
RU2011146419A (ru) 2013-05-27
AU2010237215A1 (en) 2011-09-22
TW201040530A (en) 2010-11-16
JP2012524248A (ja) 2012-10-11
IL214917A (en) 2016-03-31
JP5661738B2 (ja) 2015-01-28
KR20120027146A (ko) 2012-03-21
US20120058493A1 (en) 2012-03-08
DK2419728T3 (da) 2014-02-03
MX2011010920A (es) 2011-11-04
CN102395883B (zh) 2015-12-02
PT2419728E (pt) 2014-03-12
CA2759050A1 (en) 2010-10-21
RU2555340C2 (ru) 2015-07-10
IL214917A0 (en) 2011-11-30
CR20110513A (es) 2012-01-06
AU2010237215B2 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
HRP20201852T1 (hr) Optimizacija antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3), i njihove primjene
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
WO2017191274A3 (en) Rna encoding a therapeutic protein
MX390894B (es) Polipéptido de fusión anti-cáncer.
PH12017501583B1 (en) Novel proteins specific for cd137
HRP20140915T1 (hr) Protutijela koja služe protiv faktora rasta živaca (ngf) s poboljšanom postojanošä†u in vivo
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
IN2014DN05670A (enExample)
MX2009008118A (es) Polipeptido e2 del virus del papiloma usado para vacunacion.
MX345700B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
NZ708144A (en) Recombinant adenoviruses and use thereof
NZ612405A (en) Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests
WO2011038933A3 (en) Anti-hsv antibody
EA201391737A1 (ru) Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
HRP20140262T1 (hr) Biomarker za praä†enje pacijenata
EP3932418A3 (en) Peptides for use in promoting transport of glucose
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
BR112013005278A2 (pt) produtos vasculares acelulares
MX2019014365A (es) Tratamiento topico de la enfermedad intestinal inflamatoria usando anticuerpos y fragmentos de los mismos.
PH12017501100A1 (en) Recombinant swinepox virus and vaccines